# Tirzepatide verification FAQ — NDC, barcode, red flags, post-shortage status > Plain-language answers on how to tell if tirzepatide is legitimate, what an NDC is, how barcode verification works, why FDA ended the shortage exemption, and what the red flags for unapproved sourcing look like. ## How do I know if my tirzepatide is legitimate? Six checks reconstruct the chain of custody [13]. The product was dispensed pursuant to a valid prescription from a U.S.-licensed prescriber, after a real clinical evaluation. It was filled by a U.S. state-licensed pharmacy purchasing from the authorized U.S. distribution chain. It arrived in an original manufacturer carton with intact tamper-evident seals, a printed lot number, an NDC, and an expiration date that matches the pen or vial inside. The 2D data matrix on the carton scans successfully on the manufacturer's verification portal. The NDC validates in the public FDA NDC Directory. The product was handled cold-chain from manufacturer through dispensing. If all six hold, the chain of custody is intact. If any one is missing, the product is unverified — which is not the same as proven counterfeit, but does mean the regulatory chain that FDA approval depends on cannot be reconstructed. ## Is compounded tirzepatide still legal in 2025? With narrow exceptions, no. FDA removed tirzepatide injection from its drug-shortage list on October 2, 2024 and reaffirmed that determination in a December 19, 2024 declaratory order after litigation by the Outsourcing Facilities Association [4]. Enforcement discretion ended on February 18, 2025 for 503A state-licensed pharmacies and on March 19, 2025 for 503B outsourcing facilities. The statutory basis for compounding copies of an FDA-approved drug under FD&C Act sections 503A and 503B exists only while the drug is on the FDA shortage list. With tirzepatide off the list, that basis is gone. Patient-specific medical-need exceptions remain narrow and require documented clinical justification — they are not a workaround for routine substitution. ## How do I verify the source of tirzepatide? The most reliable patient-side checks are public and free [13]. First, scan the 2D data matrix printed on the carton at the manufacturer's verification web app. A mismatch, an error response, or a refusal to scan is itself a signal. Second, look up the NDC printed on the carton in the FDA NDC Directory at *accessdata.fda.gov/scripts/cder/ndc/*. The NDC encodes the labeler, the product, and the package configuration. Third, confirm the dispensing pharmacy is licensed in your state through your state board of pharmacy lookup, and confirm your prescriber holds an active medical license through your state medical board. Fourth, inspect the pen or vial inside the carton: lot numbers should match the carton, the tamper seal should be intact, color coding should match the labeled strength, and the expiration date should match what is printed on the box. If anything looks off, the manufacturer's patient line is the next call. ## What are the red flags that tirzepatide is fake or counterfeit? The most consistent red flags from FDA enforcement actions and analytical-chemistry reports include: marketed as "no prescription required" or sold via social-media direct messages; labeled "research only," "not for human consumption," or "for laboratory use" while including human dosing instructions; multidose vials or lyophilized powders shipped from overseas, often bundled with bacteriostatic water and syringes; pricing dramatically below the FDA-approved cash-pay or telehealth-direct price; missing NDC, lot number, expiration date, or manufacturer identifier on the carton or vial; pharmacy or "lab" name on the label not found in state board of pharmacy registries; product arriving at ambient temperature with no cold-chain packaging; sellers who cannot or will not provide a Certificate of Analysis from an accredited third-party lab [13][16]. Any one of these is a meaningful signal. Several at once is decisive. ## Can I scan my tirzepatide carton to confirm it is authentic? Yes — manufacturer-led barcode verification systems allow patients to scan the 2D data matrix on the carton and receive an immediate response on whether the unit is a verified authentic carton from the authorized supply chain [13]. A successful scan returns confirmation. A mismatch, an error message, or a result that the unit cannot be verified is itself the answer: the carton is not a recognized unit from the authorized chain. Combined with verifying the printed NDC against the FDA NDC Directory, the barcode scan is the most reliable patient-side authenticity check available. ## Why did the FDA end the tirzepatide compounding shortage exemption? The shortage exemption under FD&C Act sections 503A and 503B exists only while the FDA lists a drug as being in shortage. FDA reviews supply data and demand forecasts from manufacturers and from its own surveillance to determine when shortage status no longer reflects the market. In October 2024, FDA concluded that manufacturing capacity for tirzepatide had grown sufficient to meet projected national demand and removed tirzepatide injection from the shortage list [4]. The Outsourcing Facilities Association sued. FDA reviewed the petition and reaffirmed its determination in the December 19, 2024 declaratory order, setting the 503A enforcement-discretion sunset for February 18, 2025 and the 503B sunset for March 19, 2025. The exemption ended for the same statutory reason it had existed: the shortage status it depended on no longer applied. ## Is "research peptide" tirzepatide the same as the FDA-approved medicine? No. The phrase "research peptide" on a tirzepatide label is, in nearly every case the FDA has documented, a regulatory framing rather than a description of provenance — it places the product outside the FDA review framework for prescription drugs while signaling to buyers that the seller does not intend to take responsibility for human use [13]. The molecule, if present, may be tirzepatide. The product is not. Analytical-chemistry testing of samples marketed under these labels has documented bacterial contamination, elevated endotoxin, mismatched potency, and identity failures, including samples containing no detectable tirzepatide [12]. None of the SURPASS, SURMOUNT, or SUMMIT trial findings can be assumed to apply to such a product. ## What is the difference between FDA-approved tirzepatide and compounded versions? FDA approval is a regulatory status, not a marketing claim. The FDA-approved tirzepatide product has passed FDA review for safety, effectiveness, and manufacturing quality; it bears an approved New Drug Application; the molecule, the formulation, the delivery device, and the manufacturing facility are all part of that approval [22]. Compounded tirzepatide is — even at its best — a copy that a state-licensed pharmacy or 503B outsourcing facility prepared without FDA having reviewed that specific preparation. During the shortage period, this was permitted under a narrow statutory exemption. Post-shortage, it is not. The compounded copy may use the same active pharmaceutical ingredient or it may use an active sourced from an entirely different supply chain; the formulation matrix, the delivery format (often multidose vials), the impurity profile, and the analytical-testing rigor are generally not equivalent to the FDA-approved presentation. ## What does the FDA say about adverse events from compounded GLP-1 drugs? FDA's Adverse Event Reporting System has logged more than 1,150 adverse-event reports tied to compounded semaglutide and tirzepatide products as of July 31, 2025, including dosing errors that led to hospitalization [11]. FDA has noted explicitly that state-licensed pharmacies that are not outsourcing facilities are not federally required to report adverse events — meaning that compounded-product harm is likely substantially underreported. The reports that have surfaced have included GI events, infection-related complications, and dosing errors traced to multidose vials filled with patient-drawn syringes. FDA's own communication on this is at *fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss* [11]. ## How do I check that my prescribing telehealth clinic and pharmacy are legitimate? Two free public lookups handle most of this [13]. Your state medical board lists every licensed physician practicing in the state, with license status and any disciplinary actions. A legitimate telehealth prescriber should hold an active license in the state where you are physically located when the consultation occurs. Your state board of pharmacy lists every licensed pharmacy that can dispense to that state. A legitimate dispensing pharmacy will appear in that registry with an active license. Beyond those two checks: a pharmacy that ships tirzepatide as a multidose vial with patient-drawn syringes is, post-shortage, almost certainly outside the federal compounding framework — regardless of license status. The active pharmaceutical ingredient sourcing question (where the API came from) is harder to verify from the outside; the structural format and the lack of an FDA-approved manufacturer carton are easier. ## What is an NDC number and how do I look one up? The National Drug Code is a unique 10- or 11-digit, three-segment identifier the FDA assigns to every commercially marketed drug product in the United States. The three segments encode the labeler (the company submitting the product to FDA), the product (the active ingredient, strength, and dosage form), and the package configuration (the carton type and size). Every FDA-approved tirzepatide presentation carries its own NDC. The FDA maintains a public NDC Directory at *accessdata.fda.gov/scripts/cder/ndc/* where any NDC can be searched. A printed NDC on a carton that does not appear in the directory, or that appears under a different product or strength than what the carton claims, is a serious red flag. An absent NDC is itself a red flag — every FDA-approved prescription drug carton carries one. ## What clinical evidence supports the FDA-approved tirzepatide product? The cumulative Phase 3 program comprises the SURPASS trials in type 2 diabetes (roughly 6,000 adults across SURPASS-1 through SURPASS-5) [10], the SURMOUNT trials in obesity (SURMOUNT-1, -2, -3, -4, and the 2025 head-to-head SURMOUNT-5) [2][3][5][15], the SURPASS-CVOT cardiovascular outcomes trial in 13,165 adults with type 2 diabetes and established ASCVD [14], SURMOUNT-OSA in moderate-to-severe obstructive sleep apnea [17], SUMMIT in heart failure with preserved ejection fraction [18], and SYNERGY-NASH in biopsy-confirmed metabolic dysfunction-associated steatohepatitis [19]. Every primary endpoint across the SURPASS and SURMOUNT programs was met. Every figure cited on this site comes from studies of the FDA-approved product manufactured to GMP standards. Compounded and unapproved versions have no equivalent clinical evidence base. ## References [2] Jastreboff AM, Aronne LJ, Ahmad NN, et al. SURMOUNT-1. NEJM. 2022. DOI: 10.1056/NEJMoa2206038 [3] Aronne LJ, Horn DB, le Roux CW, et al. SURMOUNT-5. NEJM. 2025. DOI: 10.1056/NEJMoa2416394 [4] U.S. FDA. Declaratory Order: Resolution of Shortages of Tirzepatide Injection Products. 2024. [5] Garvey WT, Frias JP, Jastreboff AM, et al. SURMOUNT-2. The Lancet. 2023. DOI: 10.1016/S0140-6736(23)01200-X [10] Battelino T, Bergenstal RM, Rodriguez A, et al. SURPASS post hoc. Diabetes, Obesity and Metabolism. 2025. DOI: 10.1111/dom.16329 [11] U.S. FDA. FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss. 2025. [12] A Novel, Widespread Impurity in Mass-Compounded Tirzepatide/B12 Products. medRxiv preprint. 2026. DOI: 10.64898/2026.03.09.26347818 [13] Identify Real Lilly Medicine and Medicine Verification Web App. 2025. [14] Nicholls SJ, Bhatt DL, Buse JB, et al. SURPASS-CVOT. NEJM. 2025. DOI: 10.1056/NEJMoa2505928 [15] Aronne LJ, Sattar N, Horn DB, et al. SURMOUNT-4. JAMA. 2024. DOI: 10.1001/jama.2023.24945 [16] Safdar S, et al. Knockoff Weight Loss Drugs From Illegal Foreign Sources: Congressional Testimony. 2025. [17] Malhotra A, Grunstein RR, Fietze I, et al. SURMOUNT-OSA. NEJM. 2024. DOI: 10.1056/NEJMoa2404881 [18] Packer M, Zile MR, Kramer CM, et al. SUMMIT. NEJM. 2025. DOI: 10.1056/NEJMoa2410027 [19] Loomba R, Hartman ML, Lawitz EJ, et al. SYNERGY-NASH. NEJM. 2024. DOI: 10.1056/NEJMoa2401943 [22] U.S. FDA. FDA NDC Directory (public lookup). --- Not medical advice. This site does not sell any product and is not affiliated with any vendor or manufacturer.